Enspryng (satralizumab) / Roche  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Enspryng (satralizumab) / Roche
SHIELD DMD, NCT06450639: An Open-label Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy

Not yet recruiting
2
50
US
Satralizumab
Hoffmann-La Roche
Duchenne Muscular Dystrophy
06/26
06/27
SATISFY-JP, NCT05679570: Satralizumab in the Treatment of Pulmonary Arterial Hypertension ( Trial)

Recruiting
2
20
Japan
Satralizumab (Genetical Recombination)
International University of Health and Welfare, Japan Agency for Medical Research and Development, Keio University, Chugai Pharmaceutical
Pulmonary Arterial Hypertension
06/26
06/26

Download Options